Institutional members access full text with Ovid®

Share this article on:

New Integrase Strand Transfer Inhibitor Approved To Treat HIV-1

Aschenbrenner, Diane S. MS, RN

AJN The American Journal of Nursing: December 2013 - Volume 113 - Issue 12 - p 22
doi: 10.1097/01.NAJ.0000438862.37283.a8
Drug Watch
  • A new drug, Dolutegravir (Tivicay), has been approved to treat HIV-1 infection in both treatment-naïve patients and those who have received prior therapy against HIV infection.
  • Possible serious adverse effects of the drug include hypersensitivity and abnormal liver function if the patient is coinfected with hepatitis B or hepatitis C.

Diane S. Aschenbrenner recently retired as course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch:

© 2013 Lippincott Williams & Wilkins. All rights reserved.